Personalized medicine into health national services: barriers and potentialities
Authors:
- 3 November 2018
- journal article
- review article
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. 33 (4) , 159-163
Abstract
Research and innovation in personalized medicine (PM) are extensive and expanding, with several pharmacogenetic/pharmacogenomic (PGx) testing options currently available for a wide range of health problems. However, PGx-guided therapy faces many barriers to full integration into clinical practice and acceptance by practitioner/patient: utilization and uptake by payers in real-world practice are being discussed, and the criteria to guide clinicians and policy makers in PGx test selection are not fully incorporated. This review focuses on the advances of pharmacogenomics to individualize treatments, the relationship between pharmacogenetics and pharmacometabolomics, the new paradigm of the Big Data, the needs and barriers facing PGx clinical application and the situation of PGx testing in health national services. It is based on lectures presented by speakers of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) Fourth Conference, held in Catania, October 4th, 2017.Keywords
This publication has 15 references indexed in Scilit:
- Direct infussion Electrospray Mass Spectrometry as a new non-invasive tool for serum metabolomics in induced-stress subjectsThe European Journal of Psychiatry, 2015
- Primary-care providers’ perceived barriers to integration of genetics services: a systematic review of the literatureGenetics in Medicine, 2015
- Big Data in Medicine Is Driving Big ChangesYearbook of Medical Informatics, 2014
- Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed PharmacogenomicsClinical Pharmacology & Therapeutics, 2013
- Implementing genomic medicine in the clinic: the future is hereGenetics in Medicine, 2013
- Momentum grows to make 'personalized' medicine more 'precise'Nature Medicine, 2013
- Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomicsThe Pharmacogenomics Journal, 2012
- Deflating the Genomic BubbleScience, 2011
- Ten Years On — The Human Genome and MedicineNew England Journal of Medicine, 2010
- Personalized Medicine2004